| Date Filed | Type | Description |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2022 |
SC 13G/A
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for 908 Devices, Inc. |
| 02/04/2021 |
SC 13G
| ARCH Venture Fund VII, L.P. has filed a Schedule 13D for * 908 Devices Inc. |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2020 |
SC 13G/A
| Arch Venture Fund VII LP reports a 21.9% stake in Unity Biotechnology, Inc. |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/25/2019 |
SC 13D/A
| Arch Venture Fund VII LP has filed a Schedule 13D for Pulmatrix, Inc. |
| 03/22/2019 |
SC 13D/A
| Arch Venture Fund VII LP reports a 5.6% stake in Pulmatrix, Inc. |
| 02/14/2019 |
SC 13G
| Arch Venture Fund VII LP reports a 23.7% stake in Unity Biotechnology, Inc. |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/12/2018 |
SC 13D/A
| Arch Venture Fund VII LP reports a 9.9% stake in Pulmatrix, Inc. |
| 03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 17.7% stake in Syros Pharmaceuticals, Inc. |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 9.3% stake in Juno Therapeutics, Inc. |
| 01/05/2018 |
SC 13D/A
| Arch Venture Fund VII LP reports a 10.9% stake in Pulmatrix, Inc. |
| 02/14/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/13/2017 |
SC 13G/A
| Juno Therapeutics, Inc. reports a 10% stake in Juno Therapeutics, Inc. |
| 02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
| 06/06/2016 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership |
| 02/11/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 02/11/2016 |
SC 13G/A
| Juno Therapeutics, Inc. reports a 11.5% stake in Juno Therapeutics, Inc. |
| 02/11/2016 |
SC 13G/A
| Sage Therapeutics, Inc. has filed a Schedule 13D for Sage Therapeutics, Inc. |